Bayer AG


  • UPDATE 1-U.S. FDA rejects wider use of Xarelto drug Friday, 14 Feb 2014 | 9:31 AM ET

    NEW YORK, Feb 14- U.S. health regulators have declined to approve proposed wider uses of Bayer AG and Johnson& Johnson's lucrative blood clot preventer Xarelto, the drugmakers said on Friday. An advisory panel to the FDA concluded in January that Xarelto should not be approved to prevent new heart attacks or strokes, a use referred to as secondary prevention.

  • Feb 11- An advisory panel to the U.S. Food and Drug Administration said on Tuesday that available evidence does not prove that the painkiller naproxen, sold under the brand names Aleve and Naprosyn, carries a lower cardiac risk than rival products.

  • Feb 11- An advisory panel to the U.S. Food and Drug Administration voted on Tuesday that there is not enough evidence to show conclusively that the painkiller naproxen carries a lower cardiac risk than other popular products.

  • Regeneron forecasts strong Eylea sales; shares rise Tuesday, 11 Feb 2014 | 7:25 AM ET

    Feb 11- Regeneron Pharmaceuticals Inc forecast U.S. sales of eye drug Eylea to reach $1.7- $1.8 billion in 2014 as it expects the drug to win approval for newer uses, sending its shares up 3 percent before the opening bell. It is marketed by Bayer AG in Europe.

  • *India is biggest source of overseas medicines to U.S. NEW DELHI, Feb 10- The United States will on Monday announce a trade enforcement action linked to India, potentially dealing another blow to bilateral relations damaged in December by the arrest and strip-search of an Indian consul.

  • Feb 7- Merck& Co said on Friday it will pay $100 million to resolve all U.S. product liability lawsuits alleging it downplayed serious health risks involving its NuvaRing intrauterine contraceptive device.

  • Feb 6- Merck& Co has agreed to pay $100 million to settle hundreds of lawsuits accusing the U.S. drugmaker of downplaying serious health risks associated with its NuvaRing contraceptive device, Bloomberg reported on Thursday, citing people familiar with the deal.

  • MUMBAI/ LONDON, Feb 6- Global pharmaceutical firms are pressuring the United States to act against India to stop more local companies producing up to a dozen new varieties of cheap generic drugs still on-patent, sources with direct knowledge of the matter said.

  • Bayer bids $2.4 billion for Norway's Algeta Tuesday, 26 Nov 2013 | 2:47 AM ET

    German pharmaceutical group Bayer offered to buy Norway's Algeta for $2.4 billion, Algeta said on Tuesday.

  • Oh, baby! Confusion over free birth control Wednesday, 20 Nov 2013 | 11:07 AM ET
    Contraceptive pills.

    A majority of women are unaware birth control is available for free from health insurance plans under Obamacare, although that right faces court challenges.

  • These biotech names are ripe for takeover: Cramer Tuesday, 27 Aug 2013 | 7:19 PM ET

    We could be witnessing the beginning of a merger wave in biotech, Jim Cramer said Tuesday.

  • Amgen to buy Onyx for more than $10 billion Monday, 26 Aug 2013 | 7:51 AM ET

    Amgen has struck a $10 billion-plus deal to buy Onyx Pharmaceuticals, ending a two-month-long auction for the cancer drugmaker.

  • Bayer CEO: Environment becoming more challenging     Wednesday, 31 Jul 2013 | 5:00 AM ET

    Marijn Dekkers, CEO of drug and chemicals company Bayer, tells CNBC that falling earnings in the material sciences division may make it harder to achieve its earnings goals for the year.

  • China blocks Glaxo finance head from leaving Wednesday, 17 Jul 2013 | 11:31 AM ET

    China is preventing a GlaxoSmithKline executive from leaving the country as police accuse the British drugmaker of bribing officials and doctors, the drugmaker says.

  • Dow Chemical to Pay $1.2 Billion in Price-Fixing Case Thursday, 16 May 2013 | 9:49 AM ET

    A federal judge in Kansas City, Kansas, ordered Dow Chemical Co on Wednesday to pay $1.2 billion in a price-fixing case involving chemicals used to make foam products in cars.

  • Europe Shares Close Higher on Italy Hopes Monday, 29 Apr 2013 | 12:01 PM ET

    European shares closed higher on Monday after Italy's new Prime Minister announced his reform plans in his maiden speech to parliament.

  • Germany's Bayer has agreed to buy U.S. contraceptive devices maker Conceptus for $1.1 billion, aiming to underpin its position as the world's largest women's healthcare provider.

  • Bayer CEO: Agriculture Will Drive Profits     Thursday, 25 Apr 2013 | 6:05 AM ET

    Marijn Dekkers, CEO of Bayer, says the positive outlook for 2013 is driven by strong projected strong growth in Healthcare and Crop Sciences and explains how the company is heavily investing in its growth.

  • What Now for Western Drugmakers in India? Tuesday, 2 Apr 2013 | 7:53 PM ET

    Stung by a landmark patent defeat, Western drugmakers will be wary about launching new products in India, but they cannot afford to quit a country with a market potential as large as India's.

  • Bayer CEO: Confident of Meeting Tough Targets     Thursday, 28 Feb 2013 | 6:30 AM ET

    Marijn Dekkers, CEO of Bayer, tells CNBC why the company's development of new drugs make him confident of reaching targets set of 2.5 billion euros in drug sales.